Assignee
CRINETICS PHARMACEUTICALS INC
US·31 granted patents·22 pending applications·128 citations·filing 2016–2025
Top patents by PatentIndex Score
53 records- 0197US10981894B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2020·Granted Apr 20, 2021·6 cites·20 claims
- 0296US11186590B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2020·Granted Nov 30, 2021·6 cites·11 claims
- 0395US11834462B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2022·Granted Dec 5, 2023·2 cites·16 claims
- 0495US10766877B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Sep 8, 2020·7 cites·20 claims
- 0595US10604507B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Mar 31, 2020·7 cites·20 claims
- 0695US10562884B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Feb 18, 2020·7 cites·20 claims
- 0794US11566015B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2021·Granted Jan 31, 2023·2 cites·36 claims
- 0894US11479540B2Nonpeptide somatostatin type 5 receptor agonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2020·Granted Oct 25, 2022·5 cites·43 claims
- 0993US12134610B2Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2024·Granted Nov 5, 2024·1 cites·29 claims
- 1093US10875839B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Dec 29, 2020·5 cites·10 claims
- 1193US10696689B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Jun 30, 2020·12 cites·8 claims
- 1293US9896432B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2017·Granted Feb 20, 2018·11 cites·20 claims
- 1392US10597377B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Mar 24, 2020·8 cites·9 claims
- 1492US10351547B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2017·Granted Jul 16, 2019·9 cites·24 claims
- 1592US9902703B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2016·Granted Feb 27, 2018·8 cites·17 claims
- 1691US11414397B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2020·Granted Aug 16, 2022·2 cites·23 claims
- 1791US11072598B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Jul 27, 2021·6 cites·20 claims
- 1891US9957267B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2016·Granted May 1, 2018·8 cites·22 claims
- 1990US2026055082A1Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2088US12479828B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2023·Granted Nov 25, 2025·0 cites·22 claims
- 2188US11266641B1Formulations of a somatostatin modulatorCRINETICS PHARMACEUTICALS INC·Filed 2021·Granted Mar 8, 2022·4 cites·30 claims
- 2285US10464918B2Process of making somatostatin modulatorsCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Nov 5, 2019·6 cites·24 claims
- 2385US2024109866A1Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2483US10889561B2Process of making somatostatin modulatorsCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Jan 12, 2021·3 cites·10 claims
- 2582US2026008767A1Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2680US11773076B2Crystalline forms of a somatostatin modulatorCRINETICS PHARMACEUTICALS INC·Filed 2022·Granted Oct 3, 2023·1 cites·29 claims
- 2780US11608335B2Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2019·Granted Mar 21, 2023·2 cites·21 claims
- 2880US2022380337A1Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2974US2024376067A1Process of making somatostatin modulatorsCRINETICS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3074US2022048924A1Somatostatin modulators and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3174US2024254106A1Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3273US2024398782A1Formulations of a somatostatin modulatorCRINETICS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3369US11957674B2Formulations of a somatostatin modulatorCRINETICS PHARMACEUTICALS INC·Filed 2022·Granted Apr 16, 2024·0 cites·15 claims
- 3467US12208092B2Compositions and methods for administering paltusotine to patients with hepatic impairmentCRINETICS PHARMACEUTICALS INC·Filed 2024·Granted Jan 28, 2025·0 cites·27 claims
- 3567US2024285628A1Non-peptide targeted therapeutics and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3667US2024408247A1Non-peptide targeted therapeutics and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3766US2022144802A1Nonpeptide somatostatin type 5 receptor agonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3865US2024208963A1Crystalline melanocortin subtype-2 receptor (mc2r) antagonistCRINETICS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3964US2021087165A1Process of making somatostatin modulatorsCRINETICS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4064US2024366587A1Uses of a somatostatin modulator for the treatment of diseaseCRINETICS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 4163US2025312331A1Compositions and methods for administering paltusotine to patients with hepatic impairmentCRINETICS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 4260US2023159532A1Parathyroid hormone (pth) receptor antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4357US2022387420A1Uses of a somatostatin modulator for the treatment of diseaseCRINETICS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4454US12492181B2Gem-disubstituted piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2020·Granted Dec 9, 2025·0 cites·21 claims
- 4554US2026007758A1Somatostatin subtype-2 receptor (sst2r) non-peptide drug conjugates and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 4653US12479825B2Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2020·Granted Nov 25, 2025·0 cites·19 claims
- 4753US12466829B2Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofCRINETICS PHARMACEUTICALS INC·Filed 2020·Granted Nov 11, 2025·0 cites·19 claims
- 4853US12280046B2Melanocortin subtype-2 receptor (MC2R) antagonist for the treatment of diseaseCRINETICS PHARMACEUTICALS INC·Filed 2022·Granted Apr 22, 2025·0 cites·18 claims
- 4945US2025367190A1Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of diseaseCRINETICS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 5044US2022267295A1Crystalline forms of somatostatin modulatorsCRINETICS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
Showing the top 50 of 53 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when CRINETICS PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →